Occudo Quantitative Strategies LP Purchases Shares of 1,938 DaVita Inc. (NYSE:DVA)

Occudo Quantitative Strategies LP purchased a new stake in DaVita Inc. (NYSE:DVA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 1,938 shares of the company’s stock, valued at approximately $290,000.

Other large investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in shares of DaVita by 9.1% in the fourth quarter. Wellington Management Group LLP now owns 2,711 shares of the company’s stock valued at $405,000 after purchasing an additional 227 shares during the period. Assenagon Asset Management S.A. raised its position in shares of DaVita by 201.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company’s stock valued at $11,159,000 after purchasing an additional 49,885 shares during the period. Hussman Strategic Advisors Inc. raised its position in shares of DaVita by 200.0% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company’s stock valued at $3,769,000 after purchasing an additional 16,800 shares during the period. Caprock Group LLC bought a new position in shares of DaVita in the fourth quarter valued at about $200,000. Finally, Hennessy Advisors Inc. raised its position in shares of DaVita by 6.9% in the fourth quarter. Hennessy Advisors Inc. now owns 73,300 shares of the company’s stock valued at $10,962,000 after purchasing an additional 4,700 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DVA. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Finally, Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Trading Up 1.1%

Shares of DaVita stock opened at $145.23 on Friday. The company has a market capitalization of $11.16 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.07 and a beta of 1.14. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12-month low of $131.44 and a 12-month high of $179.60. The firm’s 50-day moving average price is $145.68 and its two-hundred day moving average price is $153.39.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.75 by $0.25. The firm had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.26 earnings per share. On average, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.